Natalia Vallianou1, Theodora Stratigou1, Gerasimos Socrates Christodoulatos2,3, Maria Dalamaga4. 1. Department of Endocrinology, Evangelismos General Hospital of Athens, 45-47 Ypsilantou street, 10676, Athens, Greece. 2. Laboratory of Microbiology, KAT Hospital, 2 Nikis, Kifisia, 14561, Athens, Greece. 3. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Mikras Asias #27, 75 Mikras Asias, Goudi, 11527, Athens, Greece. 4. Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Mikras Asias #27, 75 Mikras Asias, Goudi, 11527, Athens, Greece. madalamaga@med.uoa.gr.
Abstract
PURPOSE: In this review, we summarize current evidence on the gut microbiome and microbial metabolites in relation to obesity and obesity-associated metabolic disorders. Special emphasis is given on mechanisms interconnecting gut microbiome and microbial metabolites with metabolic disorders as well as on potential preventive and therapeutic perspectives with a "bench to bedside" approach. RECENT FINDINGS: Recent data have highlighted the role of gut dysbiosis in the etiology and pathogenesis of metabolic disorders, including obesity, metabolic syndrome, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Overall, most studies have demonstrated a reduction in gut microbiome diversity and richness in obese subjects, but there is still much debate on the exact microbial signature of a healthy or an obese gut microbiome. Despite the controversial role of an altered gut microbiome as a cause or consequence of obesity in human studies, numerous animal studies and certain human studies suggest beneficial metabolic effects of certain microbial intestinal metabolites, such as butyrate, that could be used in the prevention and treatment of obesity and its comorbidities. More randomized controlled trials and larger prospective studies including well-defined cohorts as well as a multi-omics approach are warranted to better identify the associations between the gut microbiome, microbial metabolites, and obesity and its metabolic complications.
PURPOSE: In this review, we summarize current evidence on the gut microbiome and microbial metabolites in relation to obesity and obesity-associated metabolic disorders. Special emphasis is given on mechanisms interconnecting gut microbiome and microbial metabolites with metabolic disorders as well as on potential preventive and therapeutic perspectives with a "bench to bedside" approach. RECENT FINDINGS: Recent data have highlighted the role of gut dysbiosis in the etiology and pathogenesis of metabolic disorders, including obesity, metabolic syndrome, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Overall, most studies have demonstrated a reduction in gut microbiome diversity and richness in obese subjects, but there is still much debate on the exact microbial signature of a healthy or an obesegut microbiome. Despite the controversial role of an altered gut microbiome as a cause or consequence of obesity in human studies, numerous animal studies and certain human studies suggest beneficial metabolic effects of certain microbial intestinal metabolites, such as butyrate, that could be used in the prevention and treatment of obesity and its comorbidities. More randomized controlled trials and larger prospective studies including well-defined cohorts as well as a multi-omics approach are warranted to better identify the associations between the gut microbiome, microbial metabolites, and obesity and its metabolic complications.
Authors: D Le Roy; F Di Padova; R Tees; S Lengacher; R Landmann; M P Glauser; T Calandra; D Heumann Journal: J Immunol Date: 1999-06-15 Impact factor: 5.422
Authors: Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon Journal: Nature Date: 2006-12-21 Impact factor: 49.962
Authors: Steven R Gill; Mihai Pop; Robert T Deboy; Paul B Eckburg; Peter J Turnbaugh; Buck S Samuel; Jeffrey I Gordon; David A Relman; Claire M Fraser-Liggett; Karen E Nelson Journal: Science Date: 2006-06-02 Impact factor: 47.728
Authors: Philipp M Lepper; Christian Schumann; Kathy Triantafilou; F Maximilian Rasche; Tibor Schuster; Hedwig Frank; E Marion Schneider; Martha Triantafilou; Maximilian von Eynatten Journal: J Am Coll Cardiol Date: 2007-06-18 Impact factor: 24.094
Authors: Ryan du Preez; Marie Magnusson; Marwan E Majzoub; Torsten Thomas; Christina Praeger; Christopher R K Glasson; Sunil K Panchal; Lindsay Brown Journal: Nutrients Date: 2021-05-21 Impact factor: 5.717